NCT02698280View on ClinicalTrials.gov

Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

May 31, 2018

Conditions
Glioblastoma
Interventions
DRUG

Bevacizumab

Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.

DRUG

Nimustine

Nimustine is administered intravenously at 90mg/m\^2 to 110mg/m\^2 every 6 weeks.

Trial Locations (1)

200040

Huashan hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT02698280 - Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | Biotech Hunter | Biotech Hunter